Not all individuals with CLL demand therapy. Regardless of all new advances, the iwCLL still endorses watchful observation for individuals with asymptomatic disorder.86 This advice is predicated on a minimum of two randomized trials evaluating observation to possibly chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).. in